Simplex Trading
APGE

Simplex Trading’s Apogee Therapeutics APGE Stock Holding History

Simplex Trading’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
10,700
+4,600
+75% +$414K ﹤0.01% 2388
2026
Q1 		$513K Buy
6,100
+1,500
+33% +$109K ﹤0.01% 3229
2025
Q4 		$347K Sell
4,600
-7,100
-61% -$447K ﹤0.01% 3675
2025
Q3 		$464K Sell
11,700
-7,000
-37% -$267K ﹤0.01% 3922
2025
Q2 		$812K Buy
18,700
+12,200
+188% +$464K ﹤0.01% 2991
2025
Q1 		$242K Buy
+6,500
New +$251K ﹤0.01% 4117
2024
Q4 		– Sell
-200
Closed -$11K – 8436
2024
Q3 		$11K Buy
+200
New +$9.58K ﹤0.01% 7103

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Simplex Trading's APGE Position: Q2 2026 in Review

Simplex Trading reduced its Apogee Therapeutics (APGE) stake by 97% in Q2 2026, selling an estimated $6.8M and leaving 2,368 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #4171.

Simplex Trading first reported a position in APGE in Q3 2024 and has held it in 5 quarters since. The position peaked at $6.55M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Simplex Trading held 2,368 shares of Apogee Therapeutics worth $314K as of Q2 2026.
  • Simplex Trading sold 75,440 Apogee Therapeutics shares in Q2 2026, an estimated $6.8M.
  • Apogee Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #4171 holding.
  • Simplex Trading first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Simplex Trading's Apogee Therapeutics position peaked at $6.55M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.